8BE5 image
Deposition Date 2022-10-21
Release Date 2023-11-01
Last Version Date 2024-11-06
Entry Detail
PDB ID:
8BE5
Title:
Crystal structure of SOS1-KRasG12V-Nanobody22-Nanobody75
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Lama glama (Taxon ID: 9844)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.13 Å
R-Value Free:
0.27
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
I 4 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Son of sevenless homolog 1
Gene (Uniprot):SOS1
Chain IDs:A (auth: AAZA)
Chain Length:507
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Nanobody75
Chain IDs:B (auth: C)
Chain Length:136
Number of Molecules:1
Biological Source:Lama glama
Polymer Type:polypeptide(L)
Molecule:Nanobody22
Chain IDs:D (auth: N)
Chain Length:124
Number of Molecules:1
Biological Source:Lama glama
Polymer Type:polypeptide(L)
Molecule:Isoform 2B of GTPase KRas
Mutations:G12V
Chain IDs:C (auth: R)
Chain Length:190
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Allosteric nanobodies to study the interactions between SOS1 and RAS.
Nat Commun 15 6214 6214 (2024)
PMID: 39043660 DOI: 10.1038/s41467-024-50349-2

Abstact

Protein-protein interactions (PPIs) are central in cell metabolism but research tools for the structural and functional characterization of these PPIs are often missing. Here we introduce broadly applicable immunization (Cross-link PPIs and immunize llamas, ChILL) and selection strategies (Display and co-selection, DisCO) for the discovery of diverse nanobodies that either stabilize or disrupt PPIs in a single experiment. We apply ChILL and DisCO to identify competitive, connective, or fully allosteric nanobodies that inhibit or facilitate the formation of the SOS1•RAS complex and modulate the nucleotide exchange rate on this pivotal GTPase in vitro as well as RAS signalling in cellulo. One of these connective nanobodies fills a cavity that was previously identified as the binding pocket for a series of therapeutic lead compounds. The long complementarity-determining region (CDR3) that penetrates this binding pocket serves as pharmacophore for extending the repertoire of potential leads.

Legend

Protein

Chemical

Disease

Primary Citation of related structures